Navigation Links
High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study

CHARLOTTE, N.C., Sept. 11 /PRNewswire/ -- In a new study, men with locally recurrent prostate cancer may be able to receive a promising investigational ultrasound treatment option.

A Phase III clinical trial at Specialists in Urology, located in North Naples, FL, is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT). HIFU is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves.

The lead investigator of this trial site is Dr. Nicholas Franco. This is one of several trial sites in the nation approved by the Food and Drug Administration to participate in the trial, which will begin enrolling patients in September.

HIFU is intended to eliminate cancer by elevating tissue temperatures to more than 195 degrees Fahrenheit in a matter of seconds. The Sonablate(R) 500, the therapeutic ultrasound device, which will be used in the study, is designed to destroy the entire gland in one procedure without causing damage to tissue around the prostate.

Eligible participants for the trial must be between the ages of 40 and 80, have biopsy confirmed local recurrence two or more years following EBRT, confined prostate cancer with a prostate specific antigen (PSA) greater than or equal to .5 ng/mL and less than or equal to 10 ng/mL and a Gleason score of less than or equal to seven.

For more information about enrolling in the HIFU trial, call 1-877-874-4389, or visit

This investigational treatment is performed on an outpatient basis. Potential risks of the treatment include frequency, urgency, mild discomfort or discharge in urinary stream. Less common side effects may also include urinary stricture, retention, incontinence, impotence and rectal fistula.

Prostate cancer is the most common type of non-skin cancer in American men and the second leading cause of cancer deaths in men. The American Cancer Society estimates that there were about 234,460 new cases of prostate cancer in the U.S. in 2006 and that 27,350 men die annually from the disease.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nations Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections
2. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
3. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
6. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
7. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
10. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
11. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
Post Your Comments:
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
Breaking Medicine News(10 mins):